aspirin (PLx Pharma Inc.)

PL2200 (Vazalore) is a liquid-filled aspirin formulation developed by PLx Pharma using its proprietary PLxGuard delivery technology. This formulation complexes aspirin with phospholipids (specifically phosphatidylcholine) to create a barrier that limits direct contact between the aspirin and the gastric mucosa. By doing so, it aims to reduce the risk of stomach ulcers and gastrointestinal bleeding, which are common side effects of long-term aspirin therapy. PL2200 is indicated for the secondary prevention of cardiovascular events, including myocardial infarction and stroke, by providing reliable antiplatelet activity through the irreversible inhibition of cyclooxygenase-1 (COX-1). A Phase 1 food-effect study demonstrated that PL2200 provides more consistent antiplatelet effects compared to enteric-coated aspirin, particularly in the fed state, by ensuring more reliable absorption.

Brand names

Vazalore

Other names

acetylsalicylic acid